Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s and its treatment with rituximab

Eur J Cancer. 2019 Mar:110:21-23. doi: 10.1016/j.ejca.2019.01.009. Epub 2019 Feb 7.

Authors

Martin Dutertre¹, Mathilde de Menthon¹, Nicolas Noël¹, Laurence Albiges², Olivier Lambotte³

Affiliations

¹ APHP, Service de Médecine Interne Immunologie Clinique, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre, France.
² Département d'Oncologie Médicale, Institut Gustave Roussy, Université Paris- Sud, Université Paris-Saclay, F-94800 Villejuif, France.
³ APHP, Service de Médecine Interne Immunologie Clinique, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre, France. Electronic address: [email protected].

PMID: 30739836
DOI: 10.1016/j.ejca.2019.01.009

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anemia, Hemolytic, Autoimmune / chemically induced
Anemia, Hemolytic, Autoimmune / drug therapy*
Anemia, Hemolytic, Autoimmune / immunology
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents / adverse effects*
B7-H1 Antigen / immunology
Carcinoma, Papillary / drug therapy
Carcinoma, Renal Cell / drug therapy
Female
Humans
Immunologic Factors / therapeutic use*
Kidney Neoplasms / drug therapy
Rituximab / therapeutic use*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
B7-H1 Antigen
CD274 protein, human
Immunologic Factors
Rituximab
atezolizumab